| Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors (NCT07726446) | Tianjin Medical University Cancer Institute and Hospital | 2026-10-01 |
| A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal Surgery (NCT07751367) | Tianjin Medical University Cancer Institute and Hospital | 2026-09-18 |
| Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI. (NCT07778940) | Tianjin Medical University Cancer Institute and Hospital | 2026-09-01 |
| Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07778732) | Tianjin Medical University Cancer Institute and Hospital | 2026-09-01 |
| A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC (NCT07778745) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-20 |
| Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL (NCT07724782) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-01 |
| Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II (NCT07686926) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-01 |
| A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. (NCT07729033) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-01 |
| Butyrate Yogurt for Cancer Constipation (NCT07723729) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-01 |
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer (NCT07712094) | Tianjin Medical University Cancer Institute and Hospital | 2026-08-01 |
| Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07689292) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-31 |
| To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR (NCT07738042) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-31 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC (NCT07733830) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-31 |
| Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion (NCT07738055) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-31 |
| Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors (NCT07691619) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-14 |
| Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT07721103) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-14 |
| A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs (NCT07736001) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-01 |
| Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma (NCT07665190) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-01 |
| Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer (NCT07681817) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-01 |
| Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response (NCT07670715) | Tianjin Medical University Cancer Institute and Hospital | 2026-07-01 |
| Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer (NCT07691632) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-30 |
| Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer (NCT07358689) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-30 |
| The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer (NCT07670182) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-15 |
| Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV (NCT07726433) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-15 |
| Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI (NCT07658105) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-12 |
| Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients (NCT07560475) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-10 |
| A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence (NCT07475026) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-09 |
| Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (NCT07493993) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-01 |
| Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) (NCT07584031) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-01 |
| Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy (NCT07627464) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-31 |
| Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases (NCT07570914) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer (NCT07591831) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk (NCT07515469) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery (NCT07632118) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-22 |
| The DoHAICs Study Expansion Phase (NCT07584018) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-20 |
| Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) (NCT07550920) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-10 |
| Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device (NCT07561567) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-10 |
| Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial (NCT07594925) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 |
| A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC (NCT07510594) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 |
| A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors (NCT07449481) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 |
| Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure (NCT07528274) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 |
| Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin (NCT07518706) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-30 |
| Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. (NCT07654530) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-24 |
| Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer (NCT07589972) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-20 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (NCT07372079) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-05 |
| Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer (NCT07379398) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-01 |
| Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (NCT07493382) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-01 |
| A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer (NCT07441486) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-01 |
| Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 (NCT07531979) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-01 |
| The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive (NCT06495541) | Tianjin Medical University Cancer Institute and Hospital | 2026-04-01 |
| Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma (NCT07560488) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-30 |
| The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy (NCT07681128) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-30 |
| A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NCT07491822) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-25 |
| A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (NCT07496073) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-20 |
| Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC (NCT07457528) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-12 |
| A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC (NCT07432568) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-09 |
| Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (NCT07436741) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-03 |
| A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy (NCT07584044) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-01 |
| A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer (NCT07506109) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-01 |
| Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors (NCT07444918) | Tianjin Medical University Cancer Institute and Hospital | 2026-03-01 |
| Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma (NCT07646717) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-24 |
| Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC (NCT07438600) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-24 |
| Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (NCT07410234) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-21 |
| Adebrelimab Neoadjuvant Treatment for Resectable ESCC (NCT07388095) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-15 |
| Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (NCT07277972) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-15 |
| CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL (NCT07397832) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-03 |
| A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy (NCT07548060) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-01 |
| A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer (NCT07358676) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-01 |
| Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (NCT07263360) | Tianjin Medical University Cancer Institute and Hospital | 2026-02-01 |
| Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer (NCT07302841) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-20 |
| A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance (NCT07321015) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-20 |
| Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors (NCT07330076) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-06 |
| Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (NCT07318831) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-06 |
| Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer (NCT07505173) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-01 |
| Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study (NCT07365410) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-01 |
| Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients (NCT07634978) | Tianjin Medical University Cancer Institute and Hospital | 2026-01-01 |
| A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) (NCT07324876) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-31 |
| A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma (NCT07272291) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-25 |
| Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy (NCT07330063) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-22 |
| Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases (NCT07304739) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-22 |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study (NCT07307287) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-20 |
| Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study (NCT07246330) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-15 |
| Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer (NCT07246317) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-15 |
| A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients (NCT07254416) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-15 |
| Prognostic Model of Elderly Hodgkin Lymphoma in China (NCT07374068) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-09 |
| A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors (NCT07407985) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-04 |
| Serplulimab for Locally Advanced Cervical Cancer (NCT07340489) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-03 |
| WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC (NCT07330050) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy (NCT07330037) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT07244926) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC (NCT07244874) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery (NCT07622381) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-24 |
| DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI (NCT07162506) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-03 |
| Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer (NCT07172412) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-01 |
| Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer (NCT07281157) | Tianjin Medical University Cancer Institute and Hospital | 2025-11-01 |
| Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-Center, Randomized, Two-Arm, Prospective Phase II Clinical Trial (NCT07609641) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-20 |
| A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors (NCT07351903) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-16 |
| Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo) (NCT07147426) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-01 |
| QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy (NCT07141186) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-01 |
| An Exploratory Study on Microbial Biomarkers Associated With the Efficacy of Neoadjuvant Therapy (NCT07263620) | Tianjin Medical University Cancer Institute and Hospital | 2025-10-01 |